The addition of bevacizumab (Avastin) to trabeculectomy improves the success rate of IOP control, particularly in young diabetic patients with neovascular glaucoma (NVG), according to a study published online, ahead of print, by Eye.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.